Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug
Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug is drawing significant interest across the industry.
Jiangsu Hengrui Pharmaceuticals unit Shandong Shengdi Pharmaceutical obtained approval from China's drug administrator to start clinical trials for HRS-1780 tablets. The mineralocorticoid receptor...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Hamnet review: Jessie Buckley conjures up the performance of a lifetime in a mythical Shakespearean tragedy
- IG, Lion Finance promoted to FTSE 100; easyJet, Hikma relegated
- PAN HR Solutions IPO Listing: Shares make muted debut, lists at ?78.35, just 0.44% above issue price
- ‘Clueless foreign policy’ or 'one-sided surrender'? Kharge questions Modi govt on US 'trap deal'
Source: Original →